Targeting Signal 3 Extracellularly and Intracellularly in Graft-Versus-Host Disease

Stephanie Kim1,2 and Pavan Reddy1*

1 Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States, 2 Medical Scientist Training Program, University of Michigan, Ann Arbor, MI, United States

Allogeneic hematopoietic stem cell transplantation (allo-HCT) holds curative potential for many hematological disorders. However, the pathophysiology of the desired graft-versus-tumor effect is linked to life-threatening complications of acute graft-versus-host disease (GVHD). Allogeneic donor T lymphocytes are essential for causing GVHD, and their activation relies on the coordination of TCR engagement and co-stimulation, also known as Signal 1 and Signal 2. In addition to these signals, a network of secreted cytokines by immune cells provides a third signal, Signal 3, that is critical for the initiation and maintenance of GVHD. Strategies to target Signal 3 in human diseases have shown therapeutic benefit for inflammatory disorders such as Rheumatoid Arthritis and Inflammatory Bowel Disease. However, despite our growing understanding of their role in GVHD, the success of targeting individual cytokines has been modest with some notable exceptions. This review aims to describe current approaches toward targeting Signal 3 in clinical GVHD, and to highlight emerging studies in immune cell biology that may be harnessed for better clinical translation.

Keywords: bone marrow transplantation, graft-versus-host disease, cytokines, alloimmunity, intracellular trafficking

INTRODUCTION

Acute Graft-versus-Host Disease (GVHD) is a major cause of non-relapse morbidity and mortality in patients receiving allo-HCT. While the development of GVHD is dependent on numerous factors, the HLA major and minor antigen-induced activation of donor-derived T cells is the key determinant for induction and severity of GVHD (1). T cell activation occurs as a result of the engagement of three signals (2, 3). Signal 1 is provided by the T cell receptor with cognate peptide:HLA, and Signal 2 follows the engagement of T cell co-stimulatory receptors by cognate ligands on antigen presenting cells (2). Interaction with both antigen and co-stimulatory ligands is critical for initiating the intracellular signaling cascade that promotes T cell proliferation, survival, and effector functions, and therefore a number of approaches aim to target these steps in the prevention and treatment of GVHD (4–6). In addition to these two signals, Signal 3 which is provided by surrounding cytokines controls the differentiation of T helper (Th) subsets, influences the polarization of specific T effector responses, and shapes the balance between immune activation and tolerance (3, 7, 8).

The cytokine milieu in patients following bone marrow transplantation is complex, and includes both immune cell and target tissue sources. It is released following conditioning treatments and...
amplified by tissue destruction from T cell-mediated lysis (9). In both experimental models of allo-HCT and patients affected by GVHD, the cytokines that provide Signal 3 significantly impact the alloreactive T cell response (10). Selectively targeting the cytokines that promote alloreactive T cells is therefore an attractive therapeutic strategy.

Many existing therapies for GVHD are aimed at targeting donor T cells or inflammatory byproducts of immune cells which contribute to symptoms and pathology. However, donor T cells are also critical for the graft-versus-tumor (GVT) effect, and as such, balancing therapies has been a challenge to preserve sufficient GVT activity while minimizing GVHD-related tissue damage. One strategy has been to target the cytokines that promote alloreactive T cell toxicity and also cause direct inflammation-related organ damage. While the success of these approaches has been modest thus far, a growing basic science understanding of relevant cytokines, the regulation of cytokine secretion, and the specific impact each has on immune and target cells will inform future strategies for the prevention and treatment of GVHD.

Several outstanding recent articles have reviewed the biology and the important role of cytokines in both acute and chronic GVHD (10–13). In this review, we will only highlight cytokines that serve as Signal 3 to T cells (Figure 1) and have been targeted in clinical acute GVHD. Specifically, we will first briefly review approaches that directly target Signal 3 secreted cytokines, the majority of which have been targeted upon their release extracellularly (i.e., post-synthesis and release, in the extracellular space). We will then focus on therapies that target the induction of cytokine synthesis intracellularly in immune cells, focusing on specific cell signaling pathways that lead to cytokine synthesis (i.e., pre-synthesis by targeting intracellular signaling cascades). Finally, we will review an as yet understudied area to target the cytokines following their synthesis intracellularly, including post-translational pathways, and the intracellular trafficking pathways that regulate their release. We will discuss why understanding the pathways by which these cytokines are transported intracellularly may represent an effective approach toward the rational design of GVHD therapies.

**DIRECT T CELL INTRINSIC CYTOKINES AND PROLIFERATIVE RESPONSES**

Strategies to control donor T cell activity begin with broadly acting anti-inflammatory prophylactic agents. The most widely used approaches today include methotrexate in combination with cyclosporine or tacrolimus. Methotrexate, a folate antagonist, can target rapidly proliferating allogeneic T cells and be cytotoxic to their growth. Cyclosporine and Tacrolimus inhibit the calcineurin-dependent activation of NFAT transcription factors and their translocation from the cytoplasm to the nucleus, reducing the transcription of inflammatory cytokines such as IL-2 and IFNγ by T cells. Targeting the immune response at this level inhibits key T effector functions as well as their proliferation.

While instrumental in reducing GVHD risk, however, standard prophylaxis measures are not completely effective in preventing the onset of GVHD. Furthermore, they confer nonspecific anti-inflammatory functions that can increase the risk of tumor relapse and infection. Systemic glucocorticoids which remain the mainstay of first-line treatment of acute GVHD is also broadly immunosuppressive. However, T cells are responsive to the influence of select cytokine signals which promote their growth, proliferation, cytotoxicity, and secretion of effector molecules. Important signals include cytokines that promote inflammation and which also tend to be increased following conditioning and allo-HCT such as IL-12, IL-4, IL-1, TNFα, and IL-6 (14, 15). Therefore, agents that attenuate the cytokine signals that promote the overactivity of T cells could be beneficial in GVHD treatment. While all of these cytokines have been shown to be critical sources of Signal 3, agents that block TNF, IL-6, and IL-1, as well as the T cell-derived growth factor IL-2 have been studied as potential modes of treatment in acute GVHD. There remains active interest in the use of specific anti-inflammatory cytokine blockade including agents that directly target activating cytokine signals to T cells extracellularly.

**EXTRACELLULAR SIGNAL 3 BLOCKADE**

**Anti-TNF**

Tumor Necrosis Factor (TNF) is a cytokine that acts on multiple immune cell types, and promotes the production of other Signal 3 cytokines including IL-1 and IL-6 (16). Overexpression of TNF is implicated in the development of multiple autoimmune and inflammatory disorders, and its blockade has improved disease management and quality of life for patients with rheumatoid arthritis, inflammatory bowel disease, and others (17). In addition to innate immune cell-derived TNFα, T cell-derived TNFα is implicated in the development of GVHD in experimental murine models, and in humans, it has been observed that early increased serum levels of TNFα are associated with major transplant-related complications (18, 19). TNFα levels are initially increased following conditioning treatments as measured by levels of TNF receptor-1 which correlate with those of plasma TNFα (20, 21). TNFα is appreciated to play direct roles in acute GVHD pathogenesis by both effecting direct tissue damage and by promoting allogeneic T cell cytotoxicity (22). Therefore, the use of neutralizing anti-TNFα agents has been studied for efficacy in GVHD prevention and treatment. One such agent is infliximab, an anti-TNFα monoclonal antibody that has been studied in prophylaxis, and treatment of steroid-refractory acute GVHD (SR-aGVHD) (23, 24). However, in patients with SR-aGVHD, the addition of infliximab did not improve survival and instead increased post-transplant risk of infection when compared to treatment with corticosteroids alone (24, 25). Clinical trials have also been performed to test the efficacy of etanercept for the blockade of soluble TNF. However, early results were not borne out by a multi-center randomized study that demonstrated no impact of etanercept on GVHD or on overall survival, infection, and relapse of the primary malignancy (26–30). While TNFα is best known for its inflammatory properties in promoting T cell effector responses, its dual role as a suppressive cytokine is increasingly being appreciated with the characterization of...
FIGURE 1 | Signal 3 pathways that are targeted in graft-versus-host disease (GVHD). Signal 3 critically shapes the allo-response, and existing treatment options have the potential to modulate the cytokine milieu that accompanies alloimmune T cell activation. Current treatment strategies include (a) blockade of cytokines extracellularly and blockade of cytokine receptors, and (b) inhibition of the downstream signaling cascades that culminate in the production of inflammatory cytokines. (c) The pathways that regulate cytokine secretion following their synthesis but preceding their release have not been therapeutically targeted.

functionally disparate TNF receptors and their actions on different cell types such as T regulatory cells (Tregs) (31). While the vast majority of current therapies target TNF directly, future studies of specific inhibitors of TNF production, signaling, and oligomerization, may clarify their potential in the treatment of GVHD (17).

Anti-IL-6

IL-6 is a member of a family of cytokines that shares the receptor complex gp130, a widely expressed signaling complex that leads to the activation of associated Janus kinase (JAK) and signal transducer and activation of transcription (STAT) pathways. Levels of circulating IL-6 can increase dramatically in settings of inflammation, and consequently, IL-6 is associated with the acute phase inflammatory response (32). The biological consequences of IL-6 are wide-ranging and include the pathologic stimulation of proinflammatory responses, such as by promoting Th17 cell development and inhibition of regulatory T cell differentiation (33). In murine models of GVHD, donor T cell-derived IL-6 critically contributes to disease severity, and donor T cell-specific deficiency of IL-6 decreases GVHD-related mortality (34). Blockade of the IL-6 signaling in experimental models also improved GVHD survival and led to an increase in regulatory T cells, and decreased Th1 and Th17 cells in target organs while
preserving GVT effects (34, 35). A clinical study examining the effect of tocilizumab, a humanized monoclonal antibody against the IL-6 receptor, showed favorable outcomes in a small number of patients with either acute or chronic GVHD (36). A phase I/II clinical trial further studied the effect tocilizumab administered 1 day prior to allogeneic peripheral blood stem cell transplantation in patients that received cyclosporine and methotrexate as GVHD prophylaxis (37). A phase II trial in which patients received busulfan-based conditioning prior to receiving tocilizumab with tacrolimus and methotrexate showed a low incidence of gastrointestinal GVHD (38). Recently, a phase III randomized and double-blinded trial observed a trend toward a reduced overall incidence of grade II-IV GVHD in patients receiving tocilizumab, but no difference in long term survival compared to controls (39).

**Anti-IL-1**

In addition to TNF and IL-6, IL-1 is an inflammatory cytokine that is increased following conditioning and is critical for immune homeostasis, but when dysregulated, potentiates GVHD pathology (10). Although small early studies showed that targeting soluble IL-1 with a recombinant human IL-1 receptor or administration of a recombinant IL-1 receptor antagonist could ameliorated SR-aGVHD, these results were not confirmed in a randomized controlled trial (40–42). Given its known potency in inflammatory disorders and association with GVHD in both experimental models and humans, strategies that target IL-1 may be effective depending on the phase of acute and/or chronic GVHD (43, 44). Key upstream regulators of IL-1 include intracellular immune sensors NLRP3 and NLRP6, which assemble into inflammasomes in settings of cellular damage and stress such as those induced by pre-transplant conditioning therapies. Following allogeneic transplant in experimental models, NLRP3 inflammasomes induced the secretion of pathogenic levels of IL-1β by multiple intestinal cellular sources, and also controlled the IL-1β-dependent skewing of Th17 differentiation critical to the development of GVHD (44). By contrast, donor myeloid derived suppressor cells, which have immunoregulatory functions in GVHD, can lose suppressive capacity following activation of the inflammasome (45). Thus, the cellular source is an important determinant of the impact of inflammasome dependent effects on GVHD. In host non-hematopoietic target tissues, NLRP3 inflammasomes serve a protective role in promoting intestinal epithelial cell integrity and repair by increasing IL-18 secretion (46). NLRP6, which has protective roles in intestinal colitis, plays a role in aggravating gastrointestinal GVHD when expressed in host-non-hematopoietic tissue, and its absence in host intestinal epithelial cells helps maintain gut homeostasis following allogeneic BMT in experimental models (47). It is likely that the effects mediated by NLRP6 may be IL-1 independent or dependent depending on the type of immunopathology.

**Anti-IL-2**

IL-2 expression is increased upon activation, is released by T cells, and serves as a growth factor for T effector cells and Tregs. IL-2 is one of the earliest cytokines to be studied as a target for immunosuppression therapeutically (48–50). Intracellular targeting of the production and secretion of IL-2 with calcineurin inhibitors remains the first line prophylaxis strategy in the prevention of GVHD. Studies have also explored the use of monoclonal antibodies against IL-2 receptor including daclizumab, basiliximab, and inolimomab, to target the activity of secreted IL-2. One randomized trial found that the addition of daclizumab to corticosteroids as an initial therapy for acute GVHD resulted in increased GVHD-related mortality (51). A phase II study found that while treatment of SR-aGVHD with daclizumab led to an increased complete response rate, it was associated with higher rates of long-term complications of chronic GVHD (52). Although basiliximab appears to be better tolerated by patients and not associated to the same degree of adverse events in initial studies, future studies are needed to determine its safety and efficacy (53–55). Targeting IL-2 is nuanced by its dual roles, as in addition to promoting the T cell-mediated toxicity in GVHD, it is essential for the development and maintenance of Tregs which are important regulators of immune tolerance, and may in turn be employed in the prevention of GVHD (56–60). Therefore, efforts to target IL-2 must balance its inflammatory and immunoregulatory effects that minimize GVHD but still prevent relapse of the primary disease. The administration of low-dose IL-2 is of interest in the treatment of chronic GVHD, and has been associated with expansion of Tregs, suppression of conventional T cell proliferation, and long-term reduction of chronic GVHD symptoms (61–63).

**TARGETING THE INTRACELLULAR AFFERENT ARM OF SIGNAL 3 CYTOKINE RELEASE**

Following their activation, T cells engage distinct signaling pathways that lead to the increased synthesis of important effector molecules including cytokines and cytotoxic factors. These culminate in a pro-inflammatory milieu that shapes the allogeneic T cell response and also causes direct tissue damage. While targeting cytokines following their release by immune cells is gaining increasing interest for their promising outcomes in both experimental models and clinical trials, there has been renewed interest in targeting earlier steps following T cell activation such as the intracellular signaling pathways that increase cytokine production. Therapeutic strategies have included targeting the intracellular signaling pathways that lead to proinflammatory cytokine transcription and translation with agents such as calcineurin inhibitors as described above, mTOR inhibitors, JAK inhibitors, Alpha-1 Antitrypsin, histone deacetylase inhibitors, and proteasome inhibitors.

**mTOR Inhibition**

The mammalian target of rapamycin (mTOR) pathway is a major regulator of cellular growth and metabolism that is also critical for T cell activation, differentiation, and function (64). Sirolimus, an inhibitor of mTOR, has been demonstrated to exhibit anti-inflammatory effects through multiple mechanisms including inhibition of both conventional T cell and dendritic cell activity,
and promotion of Treg development (65–67). Early studies showed that sirolimus can be well tolerated in patients and may be associated with a lower risk of GVHD (68, 69). A prospective randomized trial found that in combination with tacrolimus, sirolimus is a safe alternative to cyclosporine and methotrexate for GVHD prophylaxis (70). A recent phase III trial reported that the addition of sirolimus to cyclosporine and mycophenolate mofetil for prophylaxis showed efficacy in lowering the incidence of GVHD (71). However, its efficacy as a therapy for SR-aGVHD in combination with other agents may be limited depending on the stage of GVHD, and warrants further studies (72).

**JAK1/2 Inhibition**

T cells are responsive to inflammatory cytokines including IL-6 and interferons via their propagation of JAK/STAT pathways. Activation of the JAK family of proteins leads to the phosphorylation of STATs, which translocate to the nucleus and are critical regulators of T cell alloreactivity (73). Preclinical models demonstrated that targeting JAK1/2 targets GVHD but preserves GVL, with the contribution of decreased serum levels of proinflammatory cytokines including IL-6 (74–76). This led to testing the effects of JAK inhibitors such as ruxolitinib, baricitinib, and itacitinib. Ruxolitinib, a selective inhibitor of JAK1/2, in patients with SR-aGVHD. In an early study, six patients experienced reduced GVHD in correlation with a decrease in proinflammatory cytokines in the serum (75). Additional clinical trials are underway to examine the effects of ruxolitinib in patients with SR-aGVHD (77). Itacitinib, a selective JAK1 inhibitor, has also demonstrated safety in a phase I trial and studies of its efficacy in the treatment of SR-aGVHD are ongoing (78).

**Alpha-1 Antitrypsin**

Alpha-1 Antitrypsin (AAT) is an endogenously circulating serine protease inhibitor that, when deficient or mutated, has been described in the pathogenesis of disorders including COPD, cirrhosis, and multiple neurodegenerative diseases (79). In addition, AAT has a suppressive role in inflammatory settings with an appreciable inhibitory effect on TNF levels (80, 81). When AAT is administered in models of murine allo-HCT, it has been shown to reduce GVHD-induced mortality while preserving the allogeneic T cell GVL effect (82–84). The therapeutic benefit in these models has been linked to a decrease in alloreactive effector T cells and inflammatory cytokines, and an increase in Tregs and immunoregulatory cytokines such as IL-10 (84). AAT is an effective modulator of the profile of circulating cytokines following allo-HCT leading to significantly reduced disease murine models, underscoring the therapeutic potential of AAT and strengthening the rationale for studying the effect of AAT therapy in humans. Recent studies showed complete recovery in 4 of 12 patients and improvement in the other 8 patients with SR-aGVHD (85). A prospective multi-center study that followed tested AAT as a first line therapy for SR-aGVHD led to an overall response rate of 65% and complete response rate of 35% by day 28 (86). Ratios of T effector cells and Tregs were consistent with those observed in experimental models (86). Both studies found that AAT is well tolerated by patients, is not associated with an excessive risk of infection, and are now being studied in a randomized manner in a phase III study.

**Histone Deacetylase Inhibition**

Histone deacetylase (HDAC) inhibitors represent a diverse class of drugs that cause reversible inhibition of HDAC enzymes, remodel chromatin structure, and differentially modify gene expression depending on the specific HDAC, cell type, and context. A clinically significant consideration of HDAC inhibitors is that in addition to acting on histones, they can have non-specific effects on other protein deacetylases that broadly regulate cell growth and signaling (87). However, at non-cytotoxic doses, HDAC inhibitors have recently been appreciated to be well tolerated and exhibit immunoregulatory properties, lending to growing interest in their potential to treat inflammatory diseases (88). Among their diverse effects, HDAC inhibitors have shown immunomodulatory effects on dendritic cell and macrophage antigen presentation, TLR pathways, and IFN signaling (88). As a consequence, they can reduce the expression of cytokines involved in Th1 and Th17 differentiation such as IL-6 and IL-12 (89, 90). In experimental models of GVHD, HDAC inhibition has been observed to lead to reduced secretion of proinflammatory cytokines including IL-12, IL-6, and TNFs by dendritic cells through enhancing the expression of indoleamine 2,3 dioxygenase (91–93). Two phase II clinical trials have examined oral HDAC inhibitor vorinostat in the prevention of GVHD. One study investigated the addition of vorinostat to tacrolimus and mycophenolate in patients that received reduced intensity conditioning prior to related donor hematopoietic stem cell transplantation (94). Another study tested the effect of vorinostat when combined with tacrolimus and methotrexate following myeloablative conditioning prior to unrelated donor allo-HCT (95). Both studies showed that vorinostat is well tolerated and associated with a lower incidence of acute GVHD (94, 95). A third study is ongoing to evaluate vorinostat as preventive therapy in adolescents and young adults receiving allogeneic BMT when combined with standard preventive therapy (NCT03842696). Future studies will elucidate the clinical benefit of HDAC inhibitors including vorinostat, as well as other agents such as panobinostat that are more recently being evaluated as primary therapy for acute GVHD (96).

**Proteasome Inhibition**

The ubiquitin proteasome pathway is central to the selective maintenance of proteins, and regulates a diverse set of intracellular processes including quality control for misfolded proteins, regulation of the cell cycle, and peptide processing for antigen presentation (97). In immune cells, the proteasome is also involved in cell signaling, notably by regulating the expression of NF-κB, a transcription factor that promotes cell survival and the expression of numerous inflammatory cytokines (98). Proteasome inhibitors have thus emerged as a drug class that is associated with a number of immunomodulatory effects, and is currently approved for the treatment of a number of hematologic disorders (99). Proteasome inhibitors have been shown suppress NF-κB activation, in part due to
the reduction of proteasome-dependent degradation of IκB (100, 101). The inhibition of NF-κB is associated with reduced proliferation, survival, and toxicity of allogeneic T cells, and has also been shown to abrogate T cell cytokine production (102, 103). In addition to its effect on T cells, proteasome inhibitors such as bortezomib have suppressive effect on dendritic cell maturation and inflammatory cytokine production, while increasing dendritic cell apoptosis, highlighting their influence on multiple processes and cell types (104). In murine models of acute GVHD, treatment of recipients with bortezomib led to increased survival and protection from GVHD while maintaining GVT activity (105, 106). However, the timing of bortezomib administration may be critical in determining its efficacy as well as its overall safety, as delayed administration (i.e. 5 or more days after BMT) compared to 0 to 3 days following BMT results in increased gastrointestinal toxicity. This mechanistically correlates in other studies with amplified IL-1ß production by dendritic cells (107, 108). While an early phase I/II study to test a prophylaxis regimen of bortezomib combined with tacrolimus and methotrexate showed that this combination was well tolerated and associated with a lower incidence of GVHD, a randomized controlled trial failed to show an improvement in grade II-IV acute GVHD incidence with the addition of bortezomib, compared to methotrexate and tacrolimus alone (109, 110). Another proteasome inhibitor ixazomib improves acute GVHD upon early administration, impairs dendritic cell development, cytokine production, and expression of co-stimulatory molecules consistent with reduced proliferation of T cells, and clinical trials are underway to determine its efficacy in post-transplant patients (111).

**TARGETING THE INTRACELLULAR EFFERENT ARM OF SIGNAL 3 CYTOKINE RELEASE**

The majority of pre-clinical studies have provided the foundation for the development of therapies that target cytokines or cytokine receptors directly, or the signaling pathways that govern their transcription and translation. A gap in knowledge remains, however, in the post-translational intracellular pathways that coordinate the transport mechanisms that regulate cytokine release by immune cells. Multiple transport steps coordinate the membrane biogenesis, transport, and fusion events that carry cytokines between intracellular compartments and toward the cell surface for secretion. Better understanding of these intracellular secretory pathways utilized by cytokines in immune cells may provide important insights into novel therapeutic targets.

**The post-Golgi Apparatus Transport of Cytokines**

In the classical secretory pathway, proteins are co-translationally inserted into the endoplasmic reticulum (ER), and transported to the Golgi compartment where they undergo further processing and are delivered to other intracellular compartments, or the extracellular space. Activated T cells undergo morphologic changes that affect intracellular cytokine transport by first establishing polarity and forming immune synapses with antigen presenting cells. A dynamic cytoskeleton enables T cells to both adhere to the APC, and transport secretory vesicles containing cytokine cargoes (112). CD8+ T cells engaged with cognate APCs reorient their microtubule organizing center toward the immunological synapse, and transport secretory granules along microtubules toward the point of cell-cell contact for targeted lysis of the APC (113). CD4+ T cells remain less well characterized in their regulated secretory pathways than CD8+ T cells. However, distinct post-Golgi pathways have been elucidated, including a directional pathway that directs cytokines toward the immunological synapse and minimizes non-specific cytokine release, and a multi-directional pathway to promote more generalized inflammation (114). Studies to elucidate the molecular mediators of regulated T cell secretion may enable novel approaches toward controlling targeted cytokine release in disease states. These studies and others underscore that in addition to cytokine expression, regulation of the membrane-bound organelles that transport them significantly impact the consequences of T cell activation. However, to date, studies have been limited to understanding the secretory pathway of cytokines through events that occur after their egress from the Golgi apparatus.

**Targeting Early Intracellular Phases of the Efferent Arm of Signal 3 Release**

About one-third of encoded proteins are estimated to be targeted to the ER and destined for the secretory pathway (115, 116). Coat Protein Complex II (COPII), a complex of five highly conserved proteins (Sec23/Sec24, Sec13/Sec31, and Sar1), assembles at the ER membrane and forms vesicles that incorporates proteins for transport to the Golgi compartment, including many secreted proteins (Figure 1). The molecular components of COPII were first described in *Saccharomyces cerevisiae* (117, 118), and COPII-mediated ER-Golgi transport is conserved in all eukaryotes including humans (119). As our understanding of the COPII-dependent secretory pathway increases, the characterization of cell- and context-specific activities and regulation of protein secretion will be critical. Fundamental gaps remain in our knowledge about the role of the early secretory pathway in specific cytokine secretion, and the relevant molecular regulators of this process by immune and other cells. Recently, we have begun to decipher the role of the COPII pathway in the release of cytokines by T cells. We observed that disrupting COPII coat formation by targeting SEC23 results in greatly reduced pathogenicity of donor T cells in experimental models of GVHD (120). Future studies on how the COPII pathway regulates secretion of critical Signal 3 cytokines may further shed light on immune cell secretory pathways and provide insight into potential novel therapeutic targets.
Targeting the Timing of Signal 3 for Mitigating GVHD

Cytokine secretion and its downstream effects are dynamic and context dependent. Signal 3 cytokines are typically studied and understood as discussed above in the context of APC activation and induction of T cell response. The role of signal 3 in the perpetuation of an ongoing T cell response is unclear. Based on the known data the timing of targeting signal 3, it may be critical for mitigating GVHD. Specifically, given its role in induction of allogeneic T cell response, it may be more effective to target signal 3 in prevention strategies for either incidence of GVHD or in preventing steroid-refractoriness following onset of severe GVHD. However, because cytokine cascades and inflammatory responses may wax and wane, the exact timing will need to be carefully determined experimentally and in clinical studies.

CONCLUDING REMARKS

The relevance of cytokines that serve as Signal 3 for robust T cell responses is increasingly well established in their role in promoting GVHD, and as promising therapeutic targets. However, current approaches have yielded modest success and additional strategies are warranted. Moving forward, identifying shared intracellular trafficking pathways that control cytokine release may be of value in developing newer approaches to target Signal 3. Basic science research on the fundamental and critical determinants of intracellular trafficking pathways that coordinate their release remain to be understood. With a better mechanistic understanding of these pathways, the identification of key molecular mediators in the allogeneic setting will be essential. Exploring these questions will both enhance our fundamental understanding of immune regulation, and may pave the way for controlling T cell immunity in inflammatory disorders.

REFERENCES

1. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. (2009) 373:1550–61. doi: 10.1016/s1470-295x(09)60237-3
2. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol. (2009) 27:591–619. doi: 10.1146/annurev.immunol.021908.132706
3. Curtisinger JM, Mescher MF. Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol. (2010) 22:333–40. doi: 10.1016/j.coi.2010.02.013
4. Wallace PM, Johnson JS, MacMaster JF, Kennedy KA, Gladstone P, Linsey PS. CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. Transplantation. (1994) 58:602–10. doi: 10.1097/00007890-199409150-00013
5. Briones J, Novelli S, Sierra J. T-cell costimulatory molecules in acute-graft-versus-host disease: therapeutic implications. Bone Marrow Res. (2011) 2011:976793. doi: 10.1155/2011/976793
6. Poirier N, Mary C, Dilek N, Hervouet J, Minaud D, Blanco G, et al. Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monoclonal Fab’ antibody. Am J Transplant. (2012) 12:2630–40. doi: 10.1111/j.1600-6143.2012.01464.x
7. Curtisinger JM, Lins DC, Mescher MF. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med. (2003) 197:1141–51. doi: 10.1084/jem.20021910
8. Curtisinger JM, Schmidt CS, Mondino A, Lins DC, Kedl RM, Jenkins MK, et al. Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol. (1999) 162:3256–62.
9. Toubai T, Mathewson ND, Magesaru M, Reddy P. Danger signals and graft-versus-host disease: current understanding and future perspectives. Front Immunol. (2016) 7:539. doi: 10.3389/fimmu.2016.00539
10. Henden AS, Hill GR. Cytokines in graft-versus-host disease. J Immunol. (2015) 194:4604–12. doi: 10.4049/jimmunol.1500117
11. Kumar S, Mohammadpour H, Cao X. Targeting cytokines in GVHD therapy. J Immunol Res Ther. (2017) 2:90–9.
12. MacDonald KP, Blazar BR, Hill GR. Cytokine mediators of chronic graft-versus-host disease. J Clin Invest. (2017) 127:2452–63. doi: 10.1172/jci90593
13. Zeiser R, Blazar BR. Acute graft-versus-host disease – biologic process, prevention, and therapy. N Engl J Med. (2017) 377:2167–79. doi: 10.1056/NEJMra1609337
14.田中J, 今村M, 岩崎M, 水崎M, 木村M, 丸森H, et al. Cytokine gene expression in peripheral blood mononuclear cells during graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol. (1993) 85:558–65. doi: 10.1111/j.1365-2457.1993.tb03348.x
15. Tvedt TH, Ersvaer E, Tveita A, Brunner-Øvergaard A, Lierkink-Øvergaard S. Therapeutic intervention for chronic graft-versus-host disease: the importance of early intervention with immunosuppression. J Clin Immunol. (2003) 23:21–30. doi: 10.1023/B:jcli.0000009386.08685.00
16. O'Shea JJ, Humphries M, Brown AJ, Reiner SL, Haque S, Yin J, et al. Cytokine gene expression in peripheral blood mononuclear cells during graft-versus-host disease after allogeneic bone marrow transplantation. Nat Rev Immunol. (2002) 2:375–85. doi: 10.1038/nri8702
17. Brenner D, Blaser H, Mak TW. Regulation of tumour necrosis factor signalling: live or let die. Nat Rev Immunol. (2015) 15:362–74. doi: 10.1038/nri3834
18. Holler E, Kolb HJ, Moller A, Kempfen J, Liesenfeld S, Pechumer H, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. (1990) 75:1011–6.
19. Schmallt C, Alpdogan O, Muriglan SJ, Kappel BJ, Rotolo JA, Ricchetti ET, et al. Donor derived-TNF alpha activity in the course of post transplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha. (2003) 101:2440–5. doi: 10.1182/blood-2002-07-2109
20. Holler E, Kolb HJ, Mittermuller J, Kaul M, Ledderose G, Duell T, et al. GVHD after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of posttransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 193F). Blood. (1993) 86:890–9.
21. Kirko CE, Pacesenov S, Yanik G, Braun T, Jones D, Whitfield J, et al. Plasma elevations of tumor necrosis factor receptor-1 at day 7 postallogeic bone marrow transplantation correlate with graft-versus-host disease severity and overall survival in pediatric patients. Biol Blood Marrow Transplant. (2008) 14:759–65. doi: 10.1016/j.bbmt.2008.04.002

AUTHOR CONTRIBUTIONS

SK and PR wrote and edited the manuscript.

FUNDING

This work was supported by grants from the U.S. National Institutes of Health (NIH) [F30AI45113 (NIAID) to SK, R01HL128046 (NHLBI), R01CA203542 (NCI), and R01CA217156 (NCI) to PR].
Kim and Reddy

Targeting Signal 3 in GVHD

22. Korngold R, Marini JC, de Baca ME, Murphy GF, Gileas-Komar J. Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses. *Blood Marrow Transplant.* (2003) 9:292–303. doi: 10.1016/s1083-8791(03)00887-9

23. Hamadani M, Hofmeister CC, Jansak B, Phillips G, Elder P, Blum W, et al. Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation. *Blood Marrow Transplant.* (2008) 14:783–9. doi: 10.1038/jbmt.2008.04.006

24. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. *Blood.* (2004) 104:649–54. doi: 10.1182/blood-2003-12-2421

25. Couriel DR, Saliba R, de Lima M, Giralt S, Andersson B, Khouri I, et al. A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. *Blood Marrow Transplant.* (2009) 15:1555–62. doi: 10.1038/jbmt.2009.08.003

26. Gatta E, Braun T, Levine JE, Ferrara JL, Zhao S, Wang T, et al. Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. *Blood Marrow Transplant.* (2014) 20:1426–34. doi: 10.1038/jbmt.2014.05.023

27. De Jong CN, Saes L, Klerk CPW, Van der Klift M, Cornelissen J, Broers AE. Etanercept for steroid-refractory acute graft-versus-host disease: a single center experience. *PLoS One.* (2017) 12:e0187184. doi: 10.1371/journal.pone.0187184

28. van Groningen LF, Liefferink AM, de Haan AF, Schaap NP, Donnelly JP, et al. Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation. *Blood Marrow Transplant.* (2013) 18:114:891–900. doi: 10.1182/blood-2009-01-197178

29. Ma CKK, García-Cadenas I, Fox ML, Ai S, Nivison-Smith I, Milliken ST, et al. Microbial metabolite sensor GPR43 controls severity of experimental GVHD. *Nat Commun.* (2018) 9:3674. doi: 10.1038/s41467-018-06048-w

30. Toubai T, Fujiiwa H, Rossi C, Ci R, Miwes M, Takami H, Zajac C, et al. Host NLPR6 exacerbates graft-versus-host disease independent of gut microbial composition. *Nat Microbiol.* (2019) 4:800–12. doi: 10.1038/s41564-019-0373-1

31. Reed MH, Shapiro ME, Milford EL, Carpenter CB, Kirkman RL. Interleukin 2 receptor expression on peripheral blood lymphocytes in association with renal allograft rejection. *Transplantation.* (1989) 48:361–6. doi: 10.1097/00007890-19890306-00001

32. Abbas AK, Trottia E, Simeonov D R, Marson A, Bluestone JA. Revisiting IL-2: biology and therapeutic prospects. *Sci Immunol.* (2018) 3:eaat1482. doi: 10.1126/sciimmunol.aat1482

33. Lee SJ, Bierer BE, Gilliland DG, et al. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-resistant acute graft-versus-host disease. *Bone Marrow Transplant.* (2004) 33:1478–82. doi: 10.1038/sj.bmt.1703737

34. Schmidt-Hieber M, Fietz T, Knauf W, Uharek L, Hopfenmuller W, Thiel E, et al. Efficacy of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. *Blood.* (2002) 100:3479–82. doi: 10.1182/blood-2002-03-0985

35. Kirkman RL, Barrett LV, Gaulton GN, Kelley VE, Thyer A, Strom TB. Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs cardiac allograft survival in mice. *J Exp Med.* (1985) 162:2358–62. doi: 10.1084/jem.162.13.1358

36. Antin JH, Weisdorf D, Nicklow R, Clouthier S, Lee SJ, et al. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a phase 1/2 trial. *Transplant Proc.* (2011) 43:1928–33. doi: 10.1016/j.transproceed.2011.03.044

37. Antin JH, Weinstein HJ, Guinan EC, McCarthy P, Bierer BE, Gilliland DG, et al. Addition of interleukin-1 beta to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase II/I study of recombinant human interleukin-1 receptor antagonist in glucocorticoid-resistant graft-versus-host disease. *Transplantation.* (1996) 62:626–31. doi: 10.1007/s00079-099609150-00015

38. Antin JH, Weinstein HJ, Guinan EC, McCarthy P, Bierer BE, Gilliland DG, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. *Blood.* (1994) 84:1342–8.

39. Kennedy GA, Tey S-K, Curley C, Butler JP, Misra A, Subramoniampillai E, et al. A clinical phase I/II study of recombinant human interleukin-1 receptor in glucocorticoid-resistant graft-versus-host disease. *Blood Marrow Transplant.* (1996) 26:12141–8. doi: 10.1097/00007890-199609150-00015

40. McCarthy P, Bierer BE, Gilliland DG, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. *Biol Blood Marrow Transplant.* (2005) 11:205–11. doi: 10.1016/j.bbmt.2004.11.016

41. Antin JH, Williams L, Harris-Bacile M, Yen J, Przeportka D, Ippoliti C, et al. A clinical phase I/II study of recombinant human interleukin-1 receptor in glucocorticoid-resistant graft-versus-host disease. *Transplantation.* (1996) 62:626–31. doi: 10.1007/s00079-099609150-00015

42. Antin JH, Weinstein HJ, Guinan EC, McCarthy P, Bierer BE, Gilliland DG, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. *Blood.* (1994) 84:1342–8.

43. Antin JH, Weisdorf D, Neuberg D, Nicklow R, Clouthier S, Lee SJ, et al. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a phase 1/2 trial. *Transplant Proc.* (2011) 43:1928–33. doi: 10.1016/j.transproceed.2011.03.044

44. Schmidt-Hieber M, Fietz T, Knauf W, Uharek L, Hopfenmuller W, Thiel E, et al. Addition of interleukin-1 receptor antagonist does not prevent acute graft-versus-host disease. *Blood.* (1994) 84:1342–8.

45. Antin JH, Weisdorf D, Neuberg D, Nicklow R, Clouthier S, Lee SJ, et al. Addition of interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. *Blood.* (1994) 84:1342–8.
74. Choi J, Cooper ML, Aalamari B, Ritchey J, Collins L, Holt M, et al. Pharmacologic blockade of JAK1/JAK2 reduces GVHD and preserves the graft-versus-leukemia effect. *PLoS One*. (2014) 9:e109799. doi: 10.1371/journal.pone.0109799

75. Spoerl S, Mathew NR, Bscheider M, Schmitt-Graeff A, Chen S, Mueller T, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. *Blood*. (2014) 123:3832–42. doi: 10.1182/blood-2013-12-543736

76. Carniti G, Gimondi S, Vendramin A, Recordati C, Conflonferio D, Bemema A, et al. Pharmacologic inhibition of JAK1/JAK2 signaling reduces experimental murine acute GVHD while preserving GVT effects. *Clin Cancer Res*. (2015) 21:3740–9. doi: 10.1158/1078-0432.Ccr-14-2758

77. Jagasia M, Zeiser R, Arbushites M, Delaite P, Gadbaw B, Bubnoff NV. Ruxolitinib for the treatment of patients with steroid-refractory GVHD: An introduction to the REACH trials. *Immunotherapy*. (2018) 10:391–402. doi: 10.2217/imt-2017-0156

78. Chen Y-B, Arbushites M, Delaite P, Yan Y, Zeiser R. Trial in progress: Gravitas-301, a randomized, double-blind phase 3 study of itacitinib or placebo with corticosteroids (CS) for the first-line treatment of patients with acute GVHD (aGVHD). *Blood Marrow Transplant*. (2018) 54:2508–9. doi: 10.1038/bmt.2017.12.177

79. Carrell RW, Lomas DA. Alpha-1-antitrypsin deficiency—a model for conformational diseases. *N Engl J Med*. (2002) 346:45–53. doi: 10.1056/NEJMra010772

80. Jonigk D, Al-Omari M, Maegel L, Muller M, Izukowski N, Hong J, et al. Anti-inflammatory and immunomodulatory properties of alpha-1-antitrypsin without inhibition of elastase. *Proc Natl Acad Sci USA*. (2013) 110:15007–12. doi: 10.1073/pnas.1309648110

81. Bergin DA, Reeves EP, Hurley K, Wolfe R, Jameel R, Fitzgerald S, et al. The circulating proteinase inhibitor alpha-1-antitrypsin regulates neutrophil degranulation and autoimmunity. *Sci Transl Med*. (2014) 6:217ra1. doi: 10.1126/scitranslmed.3007116

82. Marcondes AM, Karoopongse E, Lesnikova M, Margineantu D, Welte T, Dinarello CA, et al. o-T-Antitrypsin (AAT)—modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics. *Blood*. (2014) 124:2881–91. doi: 10.1182/blood-2014-04-570440

83. Marcondes AM, Li X, Tabellini L, Bartenstein M, Kabacka J, Sale GE, et al. Inhibition of IL-32 activation by alpha-1-antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model. *Blood*. (2011) 118:5031–9. doi: 10.1182/blood-2011-07-365247

84. Tawara I, Sun Y, Lewis EC, Toubai T, Evers R, Nieves E, et al. Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. *Proc Natl Acad Sci USA*. (2012) 109:564–9. doi: 10.1073/pnas.1117665109

85. Marcondes AM, Hockenbery D, Lesnikova M, Dinarello CA, Woolfrey A, Gernsheimer T, et al. Response of steroid-refractory Acute GVHD to alpha1-antitrypsin. *Blood Marrow Transplant*. (2016) 22:1596–601. doi: 10.1016/j.bmt.2016.05.011

86. Magenau JM, Goldstein SC, Peltier D, Soiffer RJ, Braun T, Pawarode A, et al. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. *Blood*. (2002) 89:2562–73. doi: 10.1182/blood-2001-12-234712

87. Reddy P, Maeda Y, Hotary K, Liu C, Reznikov LL, Dinarello CA, et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. *Proc Natl Acad Sci USA*. (2004) 101:3921–6. doi: 10.1073/pnas.0400380101
93. Choi S, Reddy P. HDAC inhibition and graft versus host disease. Mol Med. (2011) 17:404–16. doi: 10.2119/molmed.2011.00007

94. Choi SW, Braun T, Chang I, Ferrara JL, Pawarode A, Magenau JM, et al. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol. (2014) 15:87–95. doi: 10.1016/s1470-2045(13)70512-6

95. Choi SW, Braun T, Henig I, Gatza E, Magenau J, Parkin B, et al. Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT. Blood. (2017) 130:1760–7. doi: 10.1182/blood-2017-06-790469

96. Perez L, Fernandez H, Horna P, Riches M, Locke F, Field T, et al. Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease. Bone Marrow Transplant. (2016) 51:1344–44. doi: 10.1038/s41409-018-0163-z

97. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell. (1994) 79:13–21. doi: 10.1016/0092-8674(94)90396-4

98. Chen ZJ. Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol. (1998) 1:1389–94. doi: 10.1038/ncb0805-758

99. Masanach EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. (2017) 14:417–33. doi: 10.1038/nrclinonc.2016.206

100. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res. (2001) 7:1419–28.

101. Palombella VJ, Conner EM, Fuseler JW, DeTrest D, Davis JM, Laroux FS, et al. Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA. (1998) 95:15651–6. doi: 10.1073/pnas.95.26.15671

102. Vodanovic-Jankovic S, Hari P, Jacobs P, Komorowski R, Drobyski WR. NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-3145. Blood. (2006) 107:827–34. doi: 10.1182/blood-2005-05-1820

103. Blanco B, Perez-Simon JA, Sanchez-Abbara LI, Carvajal Vergara X, Mateos J, Vidriales B, et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood. (2006) 107:3575–83. doi: 10.1182/blood-2005-05-2118

104. Al-Homsi AS, Feng Y, Duffner U, Al Malki MM, Goodyke A, Cole K, et al. Bortezomib for the prevention and treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Exp Hematol. (2016) 44:771–7. doi: 10.1016/j.exphem.2016.05.005

105. Sun K, Welniak LA, Panoskaltsis-Mortari A, O’Shaughnessy MJ, Liu H, Barao I, et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA. (2004) 101:8120–5. doi: 10.1073/pnas.0401563101

106. Pai CC, Hsiao HH, Sun K, Chen M, Hugino T, Tellez J, et al. Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels. Blood Marrow Transplant. (2014) 20:1899–904. doi: 10.1038/bmt.2014.0722

107. Sun K, Wilkins DE, Anver MR, Sayers TJ, Panoskaltsis-Mortari A, Blazar BR, et al. Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood. (2005) 106:3293–9. doi: 10.1182/blood-2004-11-4526

108. Liang Y, Ma S, Zhang Y, Wang Y, Cheng Q, Wu Y, et al. IL-1beta and TLRI4 signaling are involved in the aggravated murine acute graft-versus-host disease caused by delayed bortezomib administration. J Immunol. (2014) 192:1277–85. doi: 10.4049/jimmunol.1203428

109. Koreth J, Stevenson KE, Kim HT, McDonough SM, Bindra B, Armand P, et al. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol. (2012) 30:3202–8. doi: 10.1200/jco.2012.42.0984

110. Koreth J, Kim HT, Lange PB, Poryanda SJ, Reynolds CG, Rai SC, et al. Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results. Haematologica. (2018) 103:522–30. doi: 10.3324/haematol.2017.176859

111. Al-Homsi AS, Goodyke A, Cole K, Muilenburg M, McLane M, Abdel-Mageed S, et al. Ixazomib suppresses human dendritic cell and modulates murine graft-versus-host disease in a schedule-dependent fashion. Exp Hematol. (2017) 48:50–7. doi: 10.1016/j.exphem.2016.12.002

112. Ritter AT, Angus KL, Griffiths GM. The role of the cytoskeleton at the immunological synapse. Immunol Rev. (2013) 256:107–17. doi: 10.1111/imr.12117

113. Stinchcombe JC, Majorovits E, Bossi G, Fuller S, Griffiths GM. Centrosome polarization delivers secretory granules to the immunological synapse. Nature. (2006) 443:462–5. doi: 10.1038/nature05071

114. Huse M, Lillemie Fe, Kuhrs MS, Chen DS, Davis MM. T cells use two directionally distinct pathways for cytokine secretion. Nat Immunol. (2006) 7:247–55. doi: 10.1038/nri1304

115. Kanapin A, Batalov S, Davis MJ, Gough J, Grimmond S, Kawaji H, et al. Mouse proteome analysis. Genome Res. (2003) 13:1335–44. doi: 10.1101/gr.978703

116. Huh WK, Falvo JV, Gerke LC, Carroll AS, Howson RW, Weissman JS, et al. Global analysis of protein localization in budding yeast. Nature. (2003) 425:686–91. doi: 10.1038/nature02026

117. Novick P, Field C, Schekman R. Identification of 23 complementation groups required for post-translational events in the yeast secretory pathway. Cell. (1980) 21:205–15. doi: 10.1016/0092-8674(80)90128-2

118. Barlowe C, Orci L, Yeung T, Hosobuchi M, Hamamoto S, Salama N, et al. COPII: a membrane coat formed by Sec proteins that drive vesicle budding from the endoplasmic reticulum. Cell. (1994) 77:895–907. doi: 10.1016/0092-8674(94)90138-4

119. Schlacht A, Dacks JB. Unexpected ancient paralogs and an evolutionary model for the COPII coat complex. Genome Biol Evol. (2015) 7:1098–109. doi: 10.1093/gbe/evv045

120. Kim S, Khoriaty R, Valanparambil R, Wu J, Taylor A, Fujiwara H, et al. Targeting Sec23b in COPII vesicles regulates T cell immunity. Blood. (2018) 132(Suppl. 1):859–859. doi: 10.1182/blood-2018-99-111628

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Kim and Reddy. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.